Global life sciences mergers and acquisitions (“M&A”) activity across the biopharmaceutical, medtech, diagnostics and healthcare services sectors has accelerated significantly in 2026, with strong deal momentum expected to continue. A key driver remains the “patent cliff” – where many of the highest selling drugs lose patent protection, which is prompting larger pharmaceutical and healthcare companies to make strategic acquisitions of new products, technologies and pipelines.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Ellie
Contact Ellie, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack